BioSpace News Archive

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration

Nuance Dragon Medical One cloud-based speech recognition solution reduces burden to clinicians and helps improve quality of available cancer data

Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation, and CytoSorbents Corporation, manufacturer of the CytoSorb® extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S.

Adagio Therapeutics, Inc. announced that Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals, has joined its board of directors.

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising pipeline opportunities including with its CDK4/6 + ARK5 inhibitor ON 123300 Onconova to host conference call today at 8:30 a.m. ET NEWTOWN, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel produ

Home care services encompass a wide variety of services offered to individuals who cannot take care of themselves.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™,

ImmunoGenesis, Inc. today announced that it has been awarded a $15.5 M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance development of IMGS-001, the company’s dual specific Checkpoint Inhibitor and Tumor Microenvironment (TME) remodeling agent. IMGS-001, through its mechanism of action, has the potential to provide superior blockade of the PD-1 pathway and clear out immunosuppressive elements in the TME.

Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced the appointment of Professor Philip Sutton to their Clinical Advisory Committee and Head of the Helicobacter pylori (H. pylori) stomach bacteria development program.